Literature DB >> 8513151

Molecular biology of mutagenesis of mammalian cells by ionizing radiation.

F Hutchinson1.   

Abstract

In mammalian cells, ionizing radiation induces comparable numbers of point mutations (principally base changes, frameshifts and small deletions) and of large deletions of more than a hundred base pairs. The latter are formed either by misrepair of an end from one double-strand break with an end from another, or by a second mechanism which, it is suggested, is initiated by slowly repaired single-strand nicks. The ratio of deletions to point mutations is variable from one gene to another, and is greatest for genes in which very large deletions still allow cells to survive.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513151

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  5 in total

1.  Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation.

Authors:  Z Han; D Chatterjee; D M He; J Early; P Pantazis; J H Wyche; E A Hendrickson
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

2.  Differential activation of NF-κB and nitric oxide in lymphocytes regulates in vitro and in vivo radiosensitivity.

Authors:  Deepak Sharma; Santosh K Sandur; R Rashmi; D K Maurya; Shweta Suryavanshi; Rahul Checker; Sunil Krishnan; K B Sainis
Journal:  Mutat Res       Date:  2010-08-21       Impact factor: 2.433

3.  Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.

Authors:  Shuimei Luo; Long Chen; Xiuping Chen; Xianhe Xie
Journal:  Oncotarget       Date:  2015-06-30

4.  Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer.

Authors:  Heng Lin; Shuimei Luo; Lina Li; Sijing Zhou; Ruifen Shen; Haitao Yang; Yupeng Wu; Xianhe Xie
Journal:  Mol Clin Oncol       Date:  2017-02-03

5.  Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.

Authors:  Hongqing Zhuang; Zhiyong Yuan; Jun Wang; Lujun Zhao; Qingsong Pang; Ping Wang
Journal:  Drug Des Devel Ther       Date:  2013-10-08       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.